Summit Therapeutics, Compass Pathways, and Xortx Therapeutics are a few small-cap biopharma stocks: SMMT focuses on HER3-targeted tumors, CMPS works on psychedelic mental health therapies, and XRTX primarily targets gout nephropathy indications.
All three are small-cap clinical-stage companies, high-risk and high-volatility, completely reliant on their respective clinical data for catalysts; they'll trade sideways or decline slightly without news.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
